4//SEC Filing
Espinoza Octavio 4
Accession 0002001011-25-000015
CIK 0000886163other
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 6:55 PM ET
Size
9.1 KB
Accession
0002001011-25-000015
Insider Transaction Report
Form 4
Espinoza Octavio
Chief Financial Officer
Transactions
- Sale
Common Stock
2025-03-04$115.03/sh−5,000$575,149→ 18,879 total - Award
Common Stock
2025-03-04+7,484→ 26,363 total - Award
Employee Stock Option (right to buy)
2025-03-04+32,717→ 32,717 totalExercise: $115.26Exp: 2035-03-04→ Common Stock (32,717 underlying)
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.8900 to $115.1850, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2026; February 15, 2027; and February 15, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
- [F3]The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter.
Documents
Issuer
LIGAND PHARMACEUTICALS INC
CIK 0000886163
Entity typeother
Related Parties
1- filerCIK 0001905248
Filing Metadata
- Form type
- 4
- Filed
- Mar 5, 7:00 PM ET
- Accepted
- Mar 6, 6:55 PM ET
- Size
- 9.1 KB